Editorial: Oversight at Pitt: Whither due diligence?
By Pittsburgh Tribune-Review,
Pittsburgh Tribune-Review
| 04. 26. 2006
A superstar at the University of Pittsburgh was not subjected to commonsensical oversight by his institution.
Gerald Schatten was senior author on a paper describing patient-matched stem cells created through human embryonic cloning.
The research, conducted by Hwang Woo-Suk in South Korea, later was proven an extraordinary fraud.
It is clear Pitt's standards were substandard. The Institutional Review Board took Mr. Schatten at his word that none of the women whose eggs were harvested was identifiable to the researchers. The board, it appeared, did not have jurisdiction.
But it did.
South Korean law requires that families of women who donated eggs would have priority for any resulting treatments. So the researchers must have a way of identifying the donors. Actually, Hwang drove one, a lab assistant, to the hospital for the egg extraction. She later worked in Schatten's Pitt lab.
Strict ethical oversight protects the subjects' privacy and safety. Harvesting eggs is dangerous and questions persist whether the women gave informed consent.
Schatten may have believed all was well until it became impossible to say so with a straight face...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...